Literature DB >> 2223333

Pharmacokinetics of propofol infusions in patients with cirrhosis.

F Servin1, I D Cockshott, R Farinotti, J P Haberer, C Winckler, J M Desmonts.   

Abstract

We have compared the pharmacokinetics of propofol as an infusion in 10 control and 10 patients with cirrhosis. Anaesthesia was induced within 3-4 min during administration of an infusion of propofol 21 mg kg-1 h-1. After 5 min, the infusion was decreased in a stepwise manner to 12 mg kg-1 h-1 and subsequently 6 mg kg-1 h-1. The mean recovery time after discontinuation of the infusion was significantly longer in the cirrhotic group; however, when patients opened their eyes, blood concentrations of propofol were similar in both groups (1 micrograms ml-1). Pharmacokinetic analysis was performed from the beginning of infusion to 8 h after termination. Total body clearance was not reduced significantly in cirrhotic (1.56 (SD 0.48) litre min-1) compared with control (1.75 (0.32) litre min-1) patients. The volume of distribution at steady state was significantly greater in patients with cirrhosis than in control patients (202 (82) litre vs 121 (49) litre). However, this difference did not change terminal elimination half-life. The pharmacokinetics of propofol given by infusion to maintain general anaesthesia were not affected markedly by moderate cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223333     DOI: 10.1093/bja/65.2.177

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  25 in total

1.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

2.  Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain.

Authors:  Haruhiko Hiraoka; Koujirou Yamamoto; Soutarou Miyoshi; Toshihiro Morita; Katsunori Nakamura; Yuuji Kadoi; Fumio Kunimoto; Ryuya Horiuchi
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

Review 3.  [Anesthesia with liver failure].

Authors:  Eva-Lotte Camboni-Schellenberg; Barbara Sinner
Journal:  Anaesthesist       Date:  2016-01       Impact factor: 1.041

4.  Pharmacodynamic analysis of target-controlled infusion of propofol in patients with hepatic insufficiency.

Authors:  Jing-Ru Pan; Jun Cai; Shao-Li Zhou; Qian-Qian Zhu; Fei Huang; Yi-Han Zhang; Xin-Jin Chi; Zi-Qing Hei
Journal:  Biomed Rep       Date:  2016-10-19

5.  Enhanced sedative efficacy and delayed recovery in propofol anesthesia in a rat model of hepatic cirrhosis.

Authors:  Xuexin Chen; Rui Yan; Zhixia Bai; Hanxiang Ma
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 6.  [Perioperative anesthesia management of extended partial liver resection. Pathophysiology of hepatic diseases and functional signs of hepatic failure].

Authors:  S Herz; G Puhl; C Spies; D Jörres; P Neuhaus; C von Heymann
Journal:  Anaesthesist       Date:  2011-02       Impact factor: 1.041

Review 7.  Perioperative Evaluation and Management of Patients With Cirrhosis: Risk Assessment, Surgical Outcomes, and Future Directions.

Authors:  Kira L Newman; Kay M Johnson; Paul B Cornia; Peter Wu; Kamal Itani; George N Ioannou
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-31       Impact factor: 11.382

Review 8.  Propofol. An update of its use in anaesthesia and conscious sedation.

Authors:  H M Bryson; B R Fulton; D Faulds
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 9.  Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation.

Authors:  B Fulton; E M Sorkin
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

10.  Use of target controlled infusion to derive age and gender covariates for propofol clearance.

Authors:  Martin White; Gavin N C Kenny; Stefan Schraag
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.